SCHEMBL6925622

SCHEMBL6925622

CCN1CCN(c2ccc(-c3nc(-c4ccccc4)c[nH]3)cn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.45
RET P07949 4/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
ZAP70 P43403 1/20 0.43
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
GAA P10253 1/20 0.42
AURKA O14965 2/20 0.42
AURKB Q96GD4 2/20 0.42
KDR P35968 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925946 0.90 TDO2 (0.45) RETKDM4EALDH1A1LMNAMAPT
SCHEMBL6923696 0.90 RET (0.43) HRH3RETKDM4EZAP70GAA
SCHEMBL6926009 0.88 CNR2 (0.50) RETKDM4EMAPTZAP70AURKA
SCHEMBL6925251 0.88 RET (0.50) HRH3RETKDM4EALDH1A1ZAP70
SCHEMBL6925404 0.87 AURKA (0.55) RETKDM4EALDH1A1LMNAMAPT
SCHEMBL6925451 0.87 FYN (0.54) FYNMET
SCHEMBL6927411 0.87 KMT2A (0.47) RETKDM4ELMNAHPGDSMN1; SMN2
SCHEMBL6925387 0.86 DRD4 (0.46) RETKDM4EALDH1A1LMNAHTT
SCHEMBL6927952 0.86 CNR2 (0.48) HRH3RETKDM4EZAP70GAA
SCHEMBL6920076 0.86 RET (0.45) RETDRD4DRD3HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R HRH3 816/4885RET 1562/4885KDM4E 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.